drugset / Trial / NCT04301843
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase 2
Active not recruiting
131 enrolled
Giselle Sholler
Beat NB Cancer Foundation · collabK C Pharmaceuticals Inc. · collabTeam Parker for Life · collabUSWM, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Timeline
- Start
- 2020-09-25
- Primary completion
- 2028-10-01
- Completion
- 2033-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eflornithine | Small molecule | 1000 mg/m2 | — |